To determine the effect of leptin and post-treatment recovery on adipose tissue cellularity and apoptosis. In addition, to investigate whether Bcl-2 and/or Bax is involved in the mechanism of leptin-induced adipose tissue apoptosis. DESIGN: A total of 24 adult male Sprague-Dawley rats were injected i.c.v. with either 10 mg mouse leptin or 10 ml vehicle once per day for 4 days. At 24 h after the last injection, one group was killed while the other was monitored for 21 days. MEASUREMENTS: DNA fragmentation and Bcl-2 and Bax protein levels were determined in inguinal (ING), epididymal (EPI) and retroperitoneal (RP) white adipose tissues and the interscapular brown adipose tissue (BAT). Cellularity was determined in ING and EPI. RESULTS: Leptin significantly reduced the masses of all white fat pads [RP>ING>EPI] but not BAT. Cell volume was significantly reduced in EPI and ING. Only ING had a significantly reduced cell number from leptin treatment plus exhibited apoptosis by increased DNA fragmentation and DNA laddering, and upregulation of pro-apoptosis Bax protein. The other fat pads exhibited a general trend to increase the Bcl-2/Bax ratio. Recovery allowed for normalization of white fat pad mass, cell number and cell volume; however, BAT mass increased 42% over control. After recovery, apoptosis was not detected, Bcl-2 protein had increased in ING, and the Bcl-2/Bax ratio had risen overall. CONCLUSIONS: Central administration of mouse leptin in the rat targets white fat depots individually to reduce mass by a reduction in cell volume plus adipocyte deletion in, at least, the ING fat pad by Bax-mediated apoptosis. Even after a dramatic loss in adipose tissue mass and change in cellularity, the rat demonstrates a resilient return to control levels together with an increase in factors that prevent adipocyte loss.
Introduction
Leptin, a major regulator of food intake and energy expenditure, is increased during the accretion of body fat and circulates in the blood in concentrations proportional to body fat content.
1,2 Central and peripheral administration of recombinant leptin reduces food intake, body weight, and body fat content in rodents without functional leptin 3 and with functional leptin. [4] [5] [6] [7] [8] [9] Normal rodents treated with leptin lose more weight than rodents fed the same amount of food and the rate of regain is slower after treatment withdrawal than food-restricted rodents. 10, 11 The result is a weight loss primarily composed of fat. 4, 12 Decreased food intake does not completely account for adiposity reduction after leptin infusion. 13 Following leptin treatment, body weight and fat mass were dramatically reduced while repletion of fat depots during an 8-day recovery period was markedly delayed when compared to pair-fed rats. 14 The delay in repletion after treatment withdrawal is due, in part, to an enhanced metabolic rate and thermogenic processes maintained after treatment withdrawal. 15 In addition to increasing lipolysis, it is also possible that a loss of adipocytes 16, 17 would result in a deficit of cells for lipid esterification as the body recovers. Available adipocytes may not be able to absorb excess calories coming from a rebound in food intake. Generating new cells would require extra energy that would contribute to the prolonged metabolic enhancement seen after leptin administration. Previous studies found that leptin administration reduces epididymal and retroperitoneal cell number, 18 and induces apoptosis within retroperitoneal and parametrial fat tissues, 17 and this was not because of food restriction. Data on the duration of the impact on cell number or the mechanism of leptin-induced apoptosis are limited. Apoptosis, the regulated destruction of a cell, is a complicated process involving many factors and is continuing to be discovered. 19 Key features of apoptosis involve the mitochondria and the apoptotic proteins Bcl-2 and Bax. Overexpression of Bax accelerates apoptotic death by acting on mitochondria to disrupt the electron transport chain and promote the release of cytochrome c into the cytoplasm. 20, 21 This, in turn, activates proteolytic molecules known as caspases that are crucial for the execution of apoptosis. Bcl-2, localized to mitochondria, endoplasmic reticulum, and nuclear membranes, interferes with the activation of the caspases by preventing the release of cytochrome c. 22 Bcl-2 inhibits Baxinduced apoptosis and other mitochondrial disrupters; 23, 24 however, overexpression of Bax can counter the death repressor activity of Bcl-2. 21 The Bcl-2/Bax ratio appears to determine the susceptibility to apoptosis by regulating mitochondrial function following an apoptotic stimulus. 22 Several studies have also linked these proteins to energy metabolism and obesity. A loss of Bcl-2 expression is associated with apoptotic death of brown adipocytes while upregulation is associated with prevention of apoptosis. 25 Brown adipocytes and pancreatic b-cells of obese (fa/fa) rats were found to have lower Bcl-2 or Bcl-2/Bax mRNA and protein ratios than those of their lean littermates. 26, 27 Fatty acids can induce apoptosis of b-cells in culture, but a leptindependent maintenance of Bcl-2 expression has been found to protect against this. 27 In addition, daily injections of recombinant leptin to 21-day-old female rats caused a significant increase in Bcl-2 expression and Bcl-2/Bax ratio in granulosa cells. 28 Evidence of leptin-induced white adipose tissue apoptosis 17, 18 suggests that leptin is not acting to increase the Bcl-2/Bax ratio in these tissues but no data are available in the literature to support this or that otherwise detail the effect of leptin on this process in adipose tissue. The delay in body weight recovery after leptin administration may be related to a loss in adipocytes. The study of this phenomenon provides further insight into the metabolic control of body fat by leptin. Therefore, we hypothesize that leptin administration causes a reduction in cell size and number within adipose tissues by apoptosis. Tissues exhibiting apoptosis (DNA fragmentation) may also have a lowering of the Bcl-2/Bax ratio. Lastly, recovery should allow for the normalization of adipose tissue mass, favoring an increase in volume over cell number and an absence of apoptosis. The experimental results indicate that although all white fat pads lose a significant amount of mass, only loss in the inguinal fat pad includes apoptosis influenced by the upregulation of Bax protein. An increase of the Bcl-2/Bax ratio in the fat pads during recovery may act to prevent cell loss as the tissues show a tendency to return to control levels of adipose tissue cellularity by 21 days. We previously found that metabolic rate is enhanced during recovery from leptin administration. 15 This study expands upon the prior report by adding adipose tissue apoptosis as another contributing factor preventing a speedy weight recovery after leptin administration. Examination of adipose tissue cellularity revealed that leptin-induced changes are not permanent but provides data relevant to the physiological control of body fat. 
Methods and materials

Experimental design
Lateral cerebroventricular cannulations and injections were performed as previously described. 15 A total of 10 ml of leptin (10 mg recombinant mouse leptin, R&D Systems, Minneapolis, MN, USA) or vehicle (artificial CSF 29 ) was injected into the lateral ventricle approximately 1 h prior to the onset of the dark period. Rats received one injection per day for 4 days. This dose of leptin has been shown to induce significant weight loss by 5 days. 15 Rats were randomly assigned to treatments after being blocked into four groups of six by weight. One-half of the rats were killed 24 h after the last injection (day 4) and the others were monitored for 21 days before being killed (day 25 (180-200 mg) or BAT (40-50 mg) was homogenized in 1 ml of lysis buffer (10 mM Tris-HCl, 10 mM EDTA, and 0.5% Triton X-100, pH 8.0) in a glass-Teflon homogenizer and incubated on ice for 20 min. After centrifugation at 14 000 g for 15 min at 41C, the fat cake was removed and the supernatant containing fragmented (soluble) DNA was transferred to a new tube. DNAzol (Molecular Research Center, Cincinnati, OH, USA) (0.5 ml) was added to the pellet containing insoluble DNA. Both tubes were treated with RNase A (0.5 mg/ml) for 15-30 min at 371C. To the soluble DNA fraction, an equal volume of phenol/chloroform/isoamyl alcohol was added then vortexed briefly and centrifuged at 16 000 g for 10 min at room temperature (RT). The aqueous phase was transferred to a new tube and the organic phase reextracted with 100 ml TE buffer, pH 8.0 with centrifugation at 10 000 g for 2-3 min. To the combined aqueous phases, polyacryl carrier as recommended (Molecular Research Center), MgCl 2 (o10 mM final conc.), and 1/2 vol 7.5 M ammonium acetate were added, and then mixed by inversion. An equal volume of isopropyl alcohol was added, mixed by inversion, and allowed to precipitate for at least 20 min. The DNA precipitate was pelleted by centrifugation at 10 000 g for 30 min, and washed twice with 0.8-1 ml 70% ethanol and centrifuged at 10 000 g for 2-3 min. The large DNA fraction containing DNAzol was centrifuged at 16 000 g for 2-3 min to sediment insoluble material. The supernatant was transferred to a new tube, polyacryl carrier added, and the solution mixed by inversion. The DNA was precipitated by the addition of 1/2 vol of ethanol, mixed, and stored for 1-3 min at RT. The DNA precipitate was sedimented by centrifugation at 10 000 g for 5 min, and washed twice with 0.8-1 ml of 70% ethanol and centrifuged at 5000 g for 2-3 min. DNA pellets from both fractions were air-dried for several minutes and resolubilized in a minimal volume of TE buffer (pH 8): 20-25 ml added to the small (soluble) DNA fraction and 50-100 ml added to the large (insoluble) DNA fraction.
DNA concentration was measured using the fluorescent PicoGreen assay (Molecular Probes, Eugene, OR, USA). DNA fragmentation was calculated as soluble DNA/(soluble+inso-luble DNA) Â 100%. The soluble DNA fractions were loaded onto a 2% agarose gel and run at 128 V (8 V/cm) or on 6% TBE-polyacrylamide gels (Invitrogen, Carlsbad, CA, USA). After electrophoresis, the gel was stained with SYBR Gold (Molecular Probes) and visualized with UV light using the FluorChem Imager 8000 (Alpha Innotech, San Leandro, CA, USA) with a SYBR Gold filter (520 nm).
Western blot of Bcl-2 and Bax
The Bcl-2 and Bax proteins were detected by means of immunoblotting after the extraction of total protein from mitochondrial and cytosolic fractions of adipose tissue. White adipose tissue (WAT) (250 mg) or brown adipose tissue (BAT) (50 mg) was homogenized in a glass-Teflon homogenizer with 2 ml isolation medium (250 mM Sucrose, 10 mM HEPES, 0.2 mM potassium EDTA, ddH2O, protease inhibitors (Roche Complete s , 41C) (5:1-10:1 vol to tissue weight). The homogenate was poured into a clean centrifuge tube and centrifuged at 700 g for 10 min at 41C. The supernatant, including the fat cake, was carefully decanted into a new tube. Mitochondria were collected by centrifugation at 15 000 g for 10 min at 41C. The supernatant was transferred to a new tube for cytosolic protein isolation. The mitochondrial pellet was suspended in protein sample buffer (2% SDS, 40 mM tris base, ddH 2 O; 50-100 ml for WAT, 250-500 ml for BAT) and briefly sonicated. Protein was precipitated out of the cytosolic fraction by the addition of at least three volumes of 10% TCA in acetone, 20 mM DTT and stored at À201C for 45 min to 2 h. The solution was centrifuged at 7 500 g for 30 min at 41C. The supernatant was discarded and the pellet washed twice with 1 ml of cold 90% acetone with centrifugation at 7 500 g for 3 min at 41C. Residual acetone was removed by air-drying for 5-10 min. The pellet was dissolved in protein sample buffer (above) and sonicated briefly.
Protein content in each fraction was determined using Coomassie Plus protein assay (Pierce, Rockford, IL, USA). A total of 20-50 mg of total protein was resolved by reducing SDS-PAGE in Xcell II mini cell on 10% Bis-Tris NuPAGE gels (Invitrogen) using MOPS running buffer as recommended by the manufacturer. In addition, ECL protein molecular weight markers (RPN 2107, Amersham Biosciences, Piscataway, NJ, USA) and a Jurkat lysate as positive control (sc-2204, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were run in separate lanes, plus dotted-on peptides for Bax and Bcl-2 (#PP51 and #PP52, Oncogene, Boston, MA, USA). After electrophoresis, proteins from the gel were electroblotted onto 0.2 mm PVDF membranes following the manufacturer's directions. Each blot was stained with SYPRO Ruby (Molecular Probes) and imaged on a FluorChem Imager 8000 (Alpha Innotech, San Leandro, CA, USA) and densitometrically analyzed using ImageQuant 5.1 software 
Statistical analysis
All data are presented as the mean 7 s.e.m. and analyzed by one-way analysis of variance (ANOVA) with post hoc differences determined by the least significant difference (LSD) method. Growth performance and adipose tissue characteristics were also analyzed by two-way factorial ANOVA. Analyses were run within each fraction of each protein and not between fractions or between proteins. Differences were considered statistically significant at Po0.05. All statistical analyses were run using Statistica 6.0 for Windows (StatSoft, Tulsa, OK, USA).
Results
Body and tissue weights
Four days of i.c.v. leptin administration in normal rats caused food intake to decrease by 42% (À7.4 g/day, Po0.001) and a loss in body weight of 6% (À15.8 g) compared with pretreatment weight (273 7 2 g vs 288 7 2 g, Po0.001). After the withdrawal of treatment, the leptin group rebounded by eating 7% more (+1.2 g/day, Po0.05) than the control group during recovery, which contributed to a 38% greater weight gain (+0.93 g/day, Po0.01). By the end of recovery, the body weight of the leptin group was 2% (À7.8 g, P ¼ 0.29) lower than controls. Leptin caused significant reduction in all the white fat pad masses but not in the brown fat pad (Table 1) . Weights of the RP, EPI, and ING white fat pads were reduced by 67, 20 and 40%, respectively (all Po0.05), while BAT weight was reduced by 12% (P ¼ 0.19). There was a 31% loss in relative total WAT adjusted for body weight (g/100 g b.w., Po0.01).
Adipose tissue cellularity
As a result of the amount of tissue required for the assays, only two fat pads with the greatest amount of mass were chosen to determine cellularity, the ING and EPI white fat pads. Cell number was reduced by 46% in the ING fat pad by leptin (Po0.01; Figure 1 ), while it was reduced by 18% in the EPI pad (P ¼ 0.34). Average cell diameter was reduced similarly in both fat pads (ING, À9%, P ¼ 0.06; EPI, À11%, Po0.01; Table 1 ). Average cell volume, calculated from size distribution data, was reduced by 24 and 30% in the ING and EPI fat pads by leptin (P ¼ 0.05 and Po0.01, respectively; Figure 1 ). Cell size distribution measurements were grouped into two size ranges of small (30-69 mm) and large (70-240 mm) cells. Leptin administration caused a significant reduction in the number of large fat cells in both the ING and EPI fat pads while increasing the number of small fat cells in both pads. This was an apparent shift of cells from large size to the small size as a result of shrinking. It is also likely that more cells were moving into the small cell group than were detected. Cells smaller than 30 mm were not counted, as they cannot be reliably discerned from non-cell particles or static. 34 Following the termination of injections, every fat pad in both groups increased in mass over the 21 days of recovery but the leptin-treated rats showed a larger increase, and by day 25, there were no significant differences between groups for any white fat pad (Table 1 ). The combined total WAT mass in the leptin group was 9% smaller than control at this time (P ¼ 0.43). All cellularity attributes, cell number, diameter, and volume, within the ING and EPI white fat pads recovered to where there were no statistical differences between groups. The growth of cells over time (over 21 days of recovery) was apparent in the change in cell size distribution. In both groups, the number of small cells (30-69 mm) was reduced by day 25 with a concomitant rise in large cells (70-240 mm). There were no significant differences in the number of small or large cells at day 25 between leptin-treated and control. In contrast to the white fat pads, the brown fat pad mass, rather than normalizing to control level, increased by 127% over 21 days in those that were leptin-treated, whereas the control increased by 41% (Table 1) . The result was a brown fat mass of leptin-treated rats that was 42% greater than that of control rats on day 25 (Po0.001) and was macroscopically indistinguishable from WAT.
DNA fragmentation
Indicators of apoptosis, DNA fragmentation and DNA laddering, and proteins associated with apoptosis, Bcl-2 and Bax, were analyzed in each adipose tissue. DNA was extracted and separated into small (soluble/fragmented) and large (insoluble) DNA fractions, and a percent fragmentation calculated. The ING fat pad was the only one to have an increase in fragmentation owing to leptin treatment (2.4-fold compared to control, Po0.02; Figure 2 ). Only this tissue showed an apoptotic laddering when the small DNA fraction was run on a gel (Figure 3 ). This pattern of DNA degradation was absent in the control rats and in Adipose cellularity and apoptosis after i.c.v. leptin PS Gullicksen et al leptin-treated rats on day 25. DNA from the other adipose tissues only appeared as faint streaking and did not contain the 180-multiple base pair ladder. The combination of increased percent fragmentation and a DNA ladder strongly suggests that apoptosis occurred in the ING fat pad. The same DNA fragmentation technique was used for all the fat pads. The EPI adipose tissue produced much less fragmentation (o1%) in both groups that was significantly less than what was found in the other fat tissues. Increased fragmentation in the ING fat pad occurred without a significant change in total DNA (Figure 2 ). Leptin treatment had little impact on total DNA in any fat pad on day 4, although by day 25, total DNA in the EPI fat pad of the leptin group was significantly increased from day 4 (Po0.05). A similar trend was seen in the RP fat pad.
Bcl-2 and Bax proteins
Immunodetection of Bcl-2 and Bax proteins was carried out separately by stripping the membrane before detection of the second protein. Therefore, results for each protein should not be compared to the other, but relative changes within each protein data set should be examined. The only significant change in Bcl-2 protein levels owing to leptin treatment was a 58% increase within the cytosolic fraction of the EPI fat pad on day 4 (Po0.05; Figure 4) , although there was a trend to increase mitochondrial Bcl-2 levels in all fat pads. For Bax protein, the only change was a two-fold increase within the cytosolic fraction of the ING pad (Po0.05). The other fat pads showed a trend of decreasing Bax or no change. A combination of these changes caused a rise (EPI) or fall (ING) of the Bcl-2/Bax ratio in the cytosol. The mitochondrial Bcl-2/Bax ratio showed a trend toward an increase in all fat pads. By Day 25, previously leptin-treated rats had cytosolic Bcl-2 levels reduced to 41% of control in the EPI fat pad (P ¼ 0.20) but were increased in the ING fat pad by 67% (Po0.01) and in the brown fat pad by 69% (Po0.01). Cytosolic Bax in the ING fat pad of previously leptin-treated rats was still significantly increased by 76% (Po0.05). Overall, leptin treatment tended to increase the Bcl-2/Bax ratio within the cytosolic fraction of the EPI and brown fat pads, and within the mitochondrial fraction of all 
Discussion
In the present study, 4 days of mouse leptin injections caused significant reductions in food intake and body weight similar to previous reports. 5, 38, 39 In addition, these findings agree with previous reports of fat-specific losses during leptininduced weight loss. 4, 12 All WAT depots, but not BAT, had lost a significant amount of mass, but the degree of loss was depot specific. Cellularity was investigated in the EPI and ING fat pads. Although these fat pads were reduced in weight by leptin, they were affected differently on a cellular level. The change in EPI fat mass was because of a greater change in cell volume rather than cell number, whereas both cell number and volume were significantly reduced in the ING fat pad. Although the reduction in cell number was not statistically significant in the epididymal pad, it was previously reported that after 5 days of recombinant rat leptin (5 mg/day i.c.v.) in Sprague-Dawley rats, cell number was significantly reduced within the EPI and RP fat pads. 
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In pair-feeding studies it was indicated that the reduction in cell number by leptin, determined using a Coulter counter, was not the result of reduced food intake. 17, 18 In addition, fasting of rats for a week resulted in a 99% reduction in fat mass and a significant loss of total adipose tissue DNA content, but it did not reduce adipocyte number; rather, there was a loss of stromal-vascular cells. 40 Thus, leptin and fasting/restricted feeding provide very different signals. The lack of a loss of adipocytes during starvation has evolutionary advantages. For example, during times of undernutrition, fat cells are maintained as available storage units, essentially ready to store a valuable resource (energy as triglyceride). This observation underscores the poor performance of maintaining body weight using low-calorie diets. Exogenous leptin, on the other hand, essentially signals a large body fat store, which can be reduced by lipolysis or a combination of lipolysis plus apoptosis depending on the tissue. Examination of the distribution of cell size shows that the number of large fat cells was reduced by leptin treatment in both pads with a concomitant increase in the number of small fat cells. Simply put, large cells were shrinking into the small category, while some small cells either became smaller than 30 mm or were deleted by apoptosis. Similar changes in distribution were previously found using recombinant rat leptin (5 mg/day i.c.v.) for 5 days in 3-month-old SpragueDawley rats. 18 However, these studies did not consider changes during recovery. The inability to accurately count cells smaller than 30 mm in size is a limitation of the cellularity assay using particle counters. 34 Although the number of cells measured by the particle counter was reduced by leptin administration, it is possible that the cells could have just become smaller than the minimum measured size. If fat cells were actually being removed, there should be evidence of apoptosis. In the later stage of apoptosis, activated nucleases cause internucleosomal cleavage of DNA into small fragments resulting in an increasing amount of small (o1500 bp) soluble DNA that can be measured and related to total DNA. We found that leptin administration increased DNA fragmentation in the ING fat pad only (Figure 2 ). The ING fat pad was also the only one to show an apoptotic ladder when its DNA was run on a gel (Figure 3) . No other fat pad had a significant increase in DNA fragmentation or displayed a distinct DNA ladder. These quantitative (percent fragmentation) and visual (ladder) data provide evidence that apoptosis is occurring in, at least, the ING adipose tissue in association with leptin treatment. Although not seen in this study, DNA laddering in the RP and parametrial fat pads of normal rats treated with leptin has been found. 17 However, the rats in the prior study were treated with a recombinant rat leptin from a different source, which also appeared to have a much stronger response in most parameters, such as total body weight and adipose tissue mass. 14 In the present study, the ING fat pad had both an increase in DNA fragmentation and a reduced cell number suggesting that the deletion of adipocytes by apoptosis contributed to the reduction in fat mass. Using TdT-mediated dUTP nick end-labeling and periodic acid-Schiff's Reagent in situ staining, Qian et al 17 determined that the cells undergoing apoptosis were adipocytes. The EPI fat pads of this study, which had the smallest reduction in mass but a significant reduction in volume, had neither an increase in fragmentation nor a significant loss of cells. This suggests that the loss of mass in the EPI pads was a result of a primary loss of lipid through lipolysis. The RP fat pad, which had the largest decrease in mass during leptin injections and largest increase during recovery, likely also atrophied primarily through lipolysis rather than apoptosis. A 21-day recovery allowed for the normalization of all white fat pad weights in the leptin group (-9% overall, P ¼ 0.43) with no significant differences in cellularity or DNA fragmentation compared to that of the control group. Cell number increased similarly in both the ING and EPI fat pads. This resulted in the EPI fat pads of the leptin-treated rats having a slightly larger number of cells than that of the control rats after recovery (15%, P ¼ 0.26), whereas the ING As a possible mechanism of leptin-induced adipose tissue apoptosis, we investigated the apoptotic proteins, Bcl-2 and Bax. The ratio of anti-apoptotic proteins (ie Bcl-2) to proapoptotic proteins (ie Bax) appears to determine whether the cell undergoes apoptosis. 22 The measurements of these two proteins in the cytosolic and mitochondrial fractions from adipose tissue revealed two major leptin-induced changes: an increase in cytosolic Bcl-2 in the EPI fat pad and an increase in cytosolic Bax in the ING fat pad. The increase in Bcl-2, which raised the Bcl-2/Bax ratio, is consistent with an anti-apoptotic state like the one found in the EPI fat pad with the smallest decrease in mass and without a decrease in cell number or an increase in DNA fragmentation. There was also a general trend of higher mitochondrial Bcl-2 levels and Bcl-2/Bax ratios in all fat pads. However, the sharp increase in cytosolic Bax in the ING fat pad, lowering the Bcl-2/Bax ratio, suggests that Bax is involved in leptin-induced apoptosis in this fat pad. After 21 days of recovery, there were greater anti-apoptotic signals than there were after 4 days of leptin treatment, especially in the ING, EPI, and brown fat pads. The cytosolic Bax level in the ING pad was still high but was now opposed by an increased Bcl-2 level, improving the Bcl-2/Bax ratio. This anti-apoptotic trend may prevent the loss of cells for the support of tissue recovery and growth. The RP fat pad was the most responsive to leptin administration in reducing mass and gaining mass during recovery (five-fold increase in mass), yet there were only slight trends to increase Bcl-2/Bax ratio at days 4 and 25. This pad is likely to be more involved with lipolytic responses while maintaining cellularity for a maximal response during recovery. Since the apoptotic cycle is estimated to be between 12 and 24 h, 41 and tissue sampling was at 24 h after the last leptin injection, the detection of both DNA fragmentation and an increase in anti-apoptotic factors is possible. Also worth noting is that body weight had reached its minimum at the time of sampling, and weight gain was at its greatest after this point. 15 Thus, the animal was switching to an anabolic mode and apoptosis would not be induced. Measurement of DNA fragmentation and apoptotic protein levels closer to the time of injection may yield different results. Adipose cellularity and apoptosis after i.c.v. leptin
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The lack of apoptosis in the other adipose tissue depots vs the ING white fat pad may relate to the greater response of these tissues to increase uncoupling proteins. 15 Reactive oxygen species (ROS) are directly involved with the induction of apoptosis. 42 Leptin has been found to increase ROS in endothelial cells by increasing fatty acid oxidation via protein kinase A activation 43 or by activating the NH 2 -terminal c-Jun kinase/stress-activated protein kinase pathway, as demonstrated through enhanced JNK activity and AP-1 DNA binding. 44 Leptin also increased ROS production by stimulated polymorphonuclear neutrophils in response to infection. 45 The presence or increased activity of uncoupling proteins may prevent apoptosis by dissipating the mitochondrial proton gradient in defense against the generation of ROS. 46 The lack of a response by the ING fat pad to increase uncoupling proteins may have prevented an adequate defense against a large, acute apoptotic signal generated by leptin injections. Other reports provide evidence of an anti-apoptotic role for leptin. For example, normal islets cultured in fatty acids show a decline in Bcl-2 mRNA and apoptosis of beta cells, an effect completely blocked by leptin. 27 Increasing sympathetic output to BAT by exposure to low temperature increased the Bcl-2/Bax protein ratio 26 and reduced apoptotic cell death of brown adipocytes. [47] [48] [49] This was also mimicked by the addition of noradrenaline to brown adipocytes in culture. 26, 49 The present study similarly suggests that leptin administration increases signals, such as sympathetic outflow, to the RP and EPI white fat pads and BAT to upregulate UCP and/or the Bcl-2/Bax ratio in these tissues. Bcl-2 may function to maintain mitochondrial stability allowing uncoupling proteins to defend against leptin-induced ROS production. In contrast to the white fat pads after leptin administration, BAT did not significantly lose mass but changed from a tan color to an intensely dark brown-red, sharply demarcated mass, completely devoid of any overlying WAT. Leptin administration stimulates brown fat metabolism by increasing the number of mitochondria and content of lipogenic and thermogenic proteins. 35, 36 The rise in protein content likely offsets the loss of lipid. A 21-day recovery allowed for the normalization of WAT mass, cell number, and volume, but the brown fat pad significantly gained mass over that of control during recovery, which may be owing to the priming of the tissue for the uptake of fatty acids by increasing vascularization, lipoprotein lipase (LPL) activity, and fatty acid transporters. 36, 50 An increased vascularization and LPL content and activity also enhances the blood flow and uptake of fatty acids by BAT during leptin-induced thermogenesis. 51 The influx of fatty acids would be maintained after the leptin stimulus is removed. This, in combination with decreasing UCP activity and energy expenditure and hyperphagia, 15 favors lipid storage as the animal switches to an anabolic mode. In addition, apoptosis was not detected in BAT in this study or in previous studies that increased the noradrenergic output to BAT. 26 Therefore, BAT likely had no loss of cells but increased vascularization, which would enable the tissue to easily take up and store lipid. Similarly, the EPI fat pad, which also lacked positive indicators of apoptosis (ie an increase in DNA fragmentation), showed a larger increase in cell number and average volume after recovery compared to the ING fat pad, which had apoptosis. These conditions allowed BAT to increase mass to a level greater than control and turn into what macroscopically looked like WAT without a well-defined border. In summary, the individual response by each fat pad makes it impossible to group them together when describing the effects of leptin on adipose tissue. WAT mass is lost through leptin-induced lipolysis, 36, 37 but the ING fat pad also loses cells through apoptosis, in part, from a Bax-related pathway and a lack of a defensive mechanism because of low UCP induction. The result of apoptosis is that extra time and energy are required during recovery for the synthesis of new cells, which could contribute to a delayed body weight recovery seen after the termination of leptin administration. However, this only occurred in one fat tissue in this study.
Using a different source of leptin, previous studies have indicated apoptosis in several white fat pads coupled with a longer delay in body weight recovery. The return of adipose tissue mass and cellularity to control levels after 21 days of recovery, supported by a higher Bcl-2/Bax ratio, demonstrates the resilient nature of energy homeostasis. Future experiments using shorter recovery periods and multiple measurements would be helpful to assess the processes behind leptininduced apoptosis and changes in adipose tissue cellularity. We conclude that leptin has two actions related to apoptosis when administered i.c.v. as an acute high dose. First, leptin provides a quick, short-acting induction of apoptosis in, at least, the ING fat pad; and secondly, in a more gradual effect to induce protective factors (ie Bcl-2, UCP, ?) against further apoptosis. These likely act through different mechanisms and, if identified, could create new opportunities for anti-obesity treatments. Considering the growing number of apoptotic factors, other pathways may be involved and more research needs to be done.
